On Monday 28 May, the European Commission announced its latest initiative under the single strategy for the internal market, viz a targeted revision of the regulation concerning the Supplementary Protection Certificate (SCC) for manufacturers of generic medicines and biosimilars for non-European markets.
The adjustment could generate up to 25,000 new jobs over ten years, according to the projections of Internal Market and Industry Commissioner Elżbieta Bieńkowska, who explained at a press...